07:23 AM EST, 11/07/2025 (MT Newswires) -- ANI Pharmaceuticals ( ANIP ) reported Q3 adjusted earnings Friday of $2.04 per diluted share, up from $1.34 a year earlier.

Analysts polled by FactSet expected $1.77.

Net revenue for the quarter ended Sept. 30 was $227.8 million, compared with $148.3 million a year earlier.

Analysts surveyed by FactSet expected $212.8 million.

For 2025, ANI Pharmaceuticals ( ANIP ) said it now expects adjusted diluted EPS in the range of $7.37 to $7.64, up from its prior range of $6.98 to $7.35. Analysts polled by FactSet expect $7.32.

Net revenue for the year is now projected to be between $854 million and $873 million, up from its previous range of $818 million to $843 million. Analysts surveyed by FactSet expect $848 million.

Shares of the company were up 2% in recent Friday premarket activity.